Provided by Tiger Fintech (Singapore) Pte. Ltd.

INNOVENT BIO

100.900
+0.4000.40%
Volume:14.81M
Turnover:1.49B
Market Cap:172.84B
PE:-1.59K
High:103.200
Open:99.450
Low:97.100
Close:100.500
52wk High:109.100
52wk Low:28.650
Shares:1.71B
HK Float Shares:1.71B
Volume Ratio:0.77
T/O Rate:0.86%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.064
ROE:8.43%
ROA:3.44%
PB:10.95
PE(LYR):-1,585.36
PS:13.82

Loading ...

INNOVENT BIO (01801) Reports Interim Results with Profit of RMB 834 Million, Turning from Loss to Profit Year-over-Year

Stock News
·
Aug 27

BRIEF-Innovent Biologics Logs H1 Adjusted Net Income RMB 1,213.2 Mln

Reuters
·
Aug 27

Innovent Biologics H1 Net Income RMB 834.3 Million

THOMSON REUTERS
·
Aug 27

INNOVENT BIO (01801): Stephen A. Sherwin Appointed as Independent Non-Executive Director

Stock News
·
Aug 26

Hong Kong Stock Movement | Innovative Drug Concept Stocks See Expanding Declines as Trump Announces Swift Pharmaceutical Tariffs, Morgan Stanley Expects Low Likelihood of BD Taxation

Stock News
·
Aug 26

Innovent Biologics Announces U.S. FDA Ind Approval for the First Global Mrct Phase 3 Study (Marslight-11) of Ibi363 (Pd-1/Il-2Α-Bias) in Squamous Non-Small Cell Lung Cancer

THOMSON REUTERS
·
Aug 25

INNOVENT BIO's Yu Dechao: Chinese Innovative Drugs Face Three Major Hurdles in Global Expansion

Deep News
·
Aug 17

Innovent Biologics Logs 30% Boost in Q2 Product Revenue

MT Newswires Live
·
Aug 07

BRIEF-Innovent Biologics Reports RMB5.2 Billion Total Product Revenue In H1 2025

Reuters
·
Aug 07

Innovent Biologics Inc - Reports RMB5.2 Bln Total Product Revenue in H1 2025

THOMSON REUTERS
·
Aug 07

Innovent Biologics Receives U.S. FDA Approval for IND Application of Novel Oral GLP-1R Agonist IBI3032

Reuters
·
Aug 05

Innovent Receives U.S. FDA Approval for Ind Application of Oral Glp-1R Agonist Ibi3032

THOMSON REUTERS
·
Aug 05

Innovent Biologics Inc. Board Meeting to Address Interim Results and Dividend Recommendations

Reuters
·
Aug 04

UBS Raises INNOVENT BIO (01801) Target Price to HK$120.1, Maintains "Buy" Rating

Stock News
·
Aug 01

Innovent Biologics Announces Publication of Phase 1 Clinical Study Results for Innovative Anti-CLDN18.2 ADC, Launches Global Phase 3 Trial

Reuters
·
Jul 17

Macquarie Upgrades Innovent Biologics to Neutral from Underperform; Price Target is HK$75

MT Newswires Live
·
Jul 16

JD Health (06618.HK) Surges Nearly 4% on Strategic Alliance with Innovent Bio; Major Banks Forecast Strong H1 Earnings

Market Watcher
·
Jul 15

JD Health Jumps Nearly 4% on Innovent Partnership; Brokers Foresee Strong H1 Results

Stock Track
·
Jul 15

HK Stock Alert: JD Health International Inc. Surges Nearly 4% on Strategic Alliance with Innovent Biologics; Major Brokers Predict Strong First-Half Earnings Beat

Stock Track
·
Jul 15

Innovent Biologics May See Stronger Commercial Outlook -- Market Talk

Dow Jones
·
Jul 08